Институт стволовых клеток человека ISKJ

Институт стволовых клеток человека Balance Sheet 2006-2026 | ISKJ

Annual Balance Sheet Институт стволовых клеток человека

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006
Cash And Cash Equivalents	545 M	202 M	193 M	107 M	89.7 M	64.4 M	107 M	286 M	50.8 M	70.8 M	18.1 M	26.7 M	17.4 M	70 M	155 M	4.32 M	5.33 M	1.63 M
Total Current Assets	1.12 B	690 M	658 M	576 M	510 M	474 M	393 M	562 M	361 M	327 M	216 M	166 M	104 M	147 M	186 M	19.7 M	23.1 M	12.8 M
Property Plant Equipment Net	316 M	281 M	285 M	330 M	379 M	277 M	283 M	153 M	96.6 M	110 M	117 M	66.2 M	37 M	35.8 M	33.4 M	26.2 M	10.5 M	3.74 M
Intangible Assets	175 M	737 M	543 M	459 M	420 M	316 M	108 M	59.2 M	47.7 M	50.6 M	36.9 M	48.5 M	-	-	-	-	-	-
Goodwill And Intangible Assets	175 M	737 M	543 M	459 M	420 M	316 M	108 M	59.2 M	47.7 M	50.6 M	36.9 M	49.5 M	28.9 M	2.88 M	1.54 M	1.36 M	108 K	115 K
Long-Term Investments	161 M	112 M	95.5 M	34.5 M	-82.2 M	-	223 M	155 M	155 M	178 M	264 M	-	-	-	-	-	-	-
Tax Assets	-	83 M	86.1 M	76 M	65 M	57.4 M	22.8 M	17.8 M	13.1 M	3.26 M	2.33 M	1.6 M	6.52 M	2.14 M	260 K	245 K	276 K	48 K
Total Non Current Assets	1.43 B	1.35 B	1.08 B	936 M	889 M	651 M	660 M	477 M	471 M	479 M	513 M	837 M	877 M	148 M	86.4 M	45.6 M	13.9 M	6.92 M
Total Assets	2.54 B	2.04 B	1.74 B	1.51 B	1.4 B	1.12 B	1.05 B	1.04 B	833 M	806 M	729 M	1 B	981 M	295 M	273 M	65.3 M	37 M	19.7 M
Account Payables	53.4 M	66.8 M	102 M	97.4 M	82.6 M	122 M	72.8 M	87.6 M	19.3 M	9.3 M	16.2 M	15 M	27.2 M	6.22 M	11 M	42.8 M	21.9 M	13.3 M
Short-Term Debt	240 M	119 M	9.09 M	188 M	146 M	51.9 M	51 M	38.9 M	90 M	98.9 M	91.9 M	88.9 M	9.71 M	15 K	8 K	3.02 M	-	-
Tax Payables	-	24.6 M	14.6 M	10.7 M	4.88 M	9.01 M	6.33 M	4.28 M	2.4 M	2.07 M	6.97 M	3.43 M	4.8 M	940 K	2.85 M	2.25 M	1.15 M	186 K
Deferred Revenue	-	-	14.6 M	10.7 M	4.88 M	9.01 M	6.33 M	4.28 M	2.4 M	2.07 M	6.97 M	-	-	-	-	-	-	-
Total Current Liabilities	561 M	396 M	372 M	556 M	487 M	413 M	558 M	477 M	419 M	365 M	326 M	203 M	102 M	99.8 M	77.2 M	48.1 M	23 M	13.5 M
Long-Term Debt	547 M	713 M	608 M	301 M	278 M	323 M	363 M	307 M	24.6 M	-	37.1 M	63.1 M	739 K	-	-	-	-	-
Deferred Revenue Non Current	-	-	-	-	263 M	265 M	-	-	-	-	-	3.9 M	1.73 M	664 K	4 K	-	-	-
Deferred Tax Liabilities Non Current	-	-	-	-	318 K	2.52 M	3.51 M	15.7 M	29.7 M	18.6 M	3.18 M	3.9 M	94.4 M	-	-	-	1 K	2 K
Total Non Current Liabilities	1.01 B	1.08 B	905 M	541 M	541 M	590 M	367 M	323 M	54.4 M	18.6 M	40.2 M	129 M	61.6 M	664 K	4 K	45.8 M	1 K	2 K
Total Liabilities	1.57 B	1.47 B	1.28 B	1.1 B	1.03 B	1 B	925 M	801 M	473 M	384 M	367 M	333 M	163 M	100 M	77.2 M	48.1 M	23 M	13.5 M
Retained Earnings	318 M	146 M	94.1 M	69.4 M	-9.97 M	-94.5 M	-53.3 M	71.8 M	183 M	235 M	248 M	550 M	74.4 M	44.4 M	45.5 M	9.8 M	6.42 M	259 K
Accumulated Other Comprehensive Income Loss	-30.1 M	-	-	-	-	-178 M	-135 M	-101 M	-82.6 M	-62.9 M	-44.9 M	-24 M	-17.5 M	-11.6 M	-6.6 M	-3.04 M	-814 K	-
Total Stockholders Equity	500 M	341 M	235 M	194 M	98.7 M	27 M	51.2 M	154 M	288 M	339 M	352 M	658 M	808 M	193 M	194 M	15.8 M	12.4 M	6.26 M
Total Liabilities And Stockholders Equity	2.54 B	2.04 B	1.74 B	1.51 B	1.4 B	1.12 B	1.05 B	1.04 B	833 M	806 M	729 M	1 B	981 M	295 M	273 M	65.3 M	37 M	19.7 M
Total Investments	189 M	193 M	121 M	54.3 M	18.2 M	141 M	245 M	247 M	314 M	314 M	349 M	709 M	789 M	97.3 M	43 M	11.9 M	1.07 M	1.07 M
Total Debt	787 M	832 M	617 M	488 M	424 M	374 M	414 M	346 M	115 M	98.9 M	129 M	149 M	10.5 M	15 K	8 K	3.02 M	-	-
Net Debt	242 M	630 M	424 M	381 M	334 M	310 M	307 M	60.7 M	63.9 M	28 M	111 M	122 M	-6.91 M	-70 M	-154 M	-1.3 M	-5.33 M	-1.63 M

All numbers in RUB currency

Quarterly Balance Sheet Институт стволовых клеток человека

	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q3
Cash And Cash Equivalents	370 M	370 M	545 M	545 M	362 M	362 M	202 M	202 M	59.4 M	59.4 M	193 M	193 M	48.5 M	48.5 M	107 M	107 M	158 M	158 M	89.7 M	89.7 M	58.7 M	58.7 M	64.4 M	64.4 M	78.7 M	78.7 M	107 M	108 M	182 M	333 M	286 M	282 M	22.3 M	28.6 M	50.8 M	50.8 M	58.2 M	58.2 M	70.8 M	70.8 M	92.6 M	48.3 M	18.1 M	5.76 M	34 M	4.34 M	21.2 M
Total Current Assets	1.02 B	1.02 B	1.12 B	1.12 B	951 M	951 M	690 M	690 M	583 M	583 M	658 M	658 M	531 M	531 M	576 M	576 M	650 M	650 M	510 M	510 M	502 M	502 M	474 M	474 M	470 M	470 M	393 M	428 M	469 M	634 M	562 M	518 M	293 M	290 M	361 M	361 M	345 M	345 M	327 M	327 M	315 M	289 M	216 M	221 M	160 M	231 M	214 M
Property Plant Equipment Net	369 M	369 M	316 M	316 M	302 M	302 M	281 M	281 M	273 M	273 M	285 M	285 M	306 M	306 M	330 M	330 M	356 M	356 M	379 M	379 M	397 M	397 M	277 M	277 M	269 M	269 M	283 M	282 M	283 M	158 M	153 M	90.4 M	93.4 M	91.3 M	96.6 M	96.6 M	100 M	100 M	110 M	110 M	82.5 M	106 M	117 M	103 M	111 M	98.4 M	38.3 M
Intangible Assets	166 M	166 M	175 M	175 M	744 M	159 M	737 M	150 M	578 M	125 M	543 M	129 M	491 M	117 M	459 M	117 M	452 M	121 M	420 M	127 M	474 M	156 M	316 M	133 M	352 M	232 M	108 M	73.5 M	68 M	58.6 M	59.2 M	23 M	48.5 M	-	47.7 M	14.8 M	51.2 M	21.2 M	21.6 M	21.6 M	43.9 M	-	16.4 M	-	93.2 M	-	-
Goodwill And Intangible Assets	166 M	166 M	175 M	175 M	744 M	159 M	737 M	150 M	578 M	125 M	543 M	129 M	491 M	117 M	459 M	117 M	452 M	121 M	420 M	127 M	474 M	156 M	316 M	133 M	352 M	232 M	108 M	73.5 M	68 M	58.6 M	59.2 M	23 M	48.5 M	46.4 M	47.7 M	14.8 M	51.2 M	21.2 M	21.6 M	21.6 M	43.9 M	6.39 M	16.4 M	17.2 M	94.2 M	23.9 M	20.5 M
Long-Term Investments	161 M	161 M	161 M	161 M	208 M	213 M	112 M	193 M	105 M	167 M	121 M	121 M	73 M	73.5 M	34.5 M	54.3 M	-6.94 M	31.8 M	-82.2 M	18.2 M	-110 M	15.2 M	-	3 K	-153 M	-	223 M	153 M	162 M	245 M	155 M	314 M	200 M	23.9 M	155 M	314 M	197 M	343 M	314 M	314 M	217 M	650 M	349 M	688 M	-	645 M	634 M
Tax Assets	-	-	-	-	89 M	-	83 M	-	87.1 M	-	86.1 M	-	81.1 M	-	76 M	-	76.5 M	-	65 M	-	37.1 M	-	57.4 M	-	30.5 M	-	22.8 M	14.4 M	13.6 M	-	17.8 M	-	5.02 M	290 M	13.1 M	-	3.58 M	-	-	-	2.98 M	1.68 M	-	4 K	1.51 M	350 K	-
Total Non Current Assets	1.49 B	1.49 B	1.43 B	1.43 B	1.4 B	1.4 B	1.35 B	1.35 B	1.17 B	1.17 B	1.08 B	1.08 B	969 M	969 M	936 M	936 M	937 M	937 M	889 M	889 M	924 M	924 M	651 M	651 M	653 M	653 M	660 M	616 M	611 M	483 M	477 M	466 M	461 M	463 M	471 M	471 M	499 M	499 M	479 M	479 M	517 M	912 M	513 M	898 M	1.01 B	851 M	747 M
Total Assets	2.51 B	2.51 B	2.54 B	2.54 B	2.36 B	2.36 B	2.04 B	2.04 B	1.75 B	1.75 B	1.74 B	1.74 B	1.5 B	1.5 B	1.51 B	1.51 B	1.59 B	1.59 B	1.4 B	1.4 B	1.43 B	1.43 B	1.12 B	1.12 B	1.12 B	1.12 B	1.05 B	1.04 B	1.08 B	1.12 B	1.04 B	984 M	754 M	818 M	833 M	833 M	844 M	844 M	806 M	806 M	832 M	1.2 B	729 M	1.12 B	1.17 B	1.08 B	961 M
Account Payables	28 M	28 M	53.4 M	53.4 M	147 M	32.8 M	66.8 M	33.9 M	111 M	54.6 M	102 M	35.9 M	89.8 M	89.8 M	97.4 M	35.4 M	104 M	32.1 M	82.6 M	41.1 M	73 M	73 M	122 M	79.9 M	85.4 M	70.9 M	72.8 M	57.1 M	100 M	83 M	87.6 M	30.7 M	52.3 M	18 M	19.3 M	15.4 M	10.7 M	5.36 M	3.97 M	3.97 M	18.4 M	247 M	6.02 M	193 M	4.71 M	182 M	-
Short-Term Debt	198 M	198 M	240 M	240 M	101 M	101 M	119 M	119 M	8.61 M	8.61 M	9.09 M	9.09 M	158 M	158 M	188 M	188 M	181 M	181 M	146 M	146 M	43.9 M	43.9 M	51.9 M	51.9 M	66.5 M	66.5 M	51 M	42.7 M	40.3 M	45.8 M	38.9 M	78.8 M	59.9 M	97.1 M	90 M	90 M	91.4 M	91.4 M	98.9 M	98.9 M	108 M	81.9 M	91.9 M	90.1 M	89 M	88.8 M	70.4 M
Tax Payables	-	-	-	-	32.1 M	-	24.6 M	-	16.8 M	-	14.6 M	-	10.2 M	-	10.7 M	-	4.69 M	-	4.88 M	-	14.2 M	-	9.01 M	-	13 M	-	6.33 M	6.74 M	6.04 M	-	4.28 M	-	3.89 M	-	2.4 M	-	3.26 M	-	-	-	5.71 M	7.14 M	-	-	4.46 M	4.84 M	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	14.6 M	-	10.2 M	-	10.7 M	-	4.69 M	-	4.88 M	-	70.8 M	-	9.01 M	-	13 M	-	6.33 M	6.74 M	6.04 M	-	4.28 M	-	3.89 M	-	2.4 M	-	3.26 M	-	-	-	5.71 M	10.5 M	-	-	-	9.28 M	-
Total Current Liabilities	540 M	540 M	561 M	561 M	455 M	455 M	396 M	396 M	294 M	294 M	372 M	372 M	403 M	403 M	556 M	556 M	460 M	460 M	487 M	487 M	411 M	411 M	413 M	413 M	585 M	585 M	558 M	458 M	496 M	499 M	477 M	406 M	419 M	416 M	419 M	419 M	362 M	362 M	365 M	365 M	336 M	340 M	326 M	283 M	152 M	280 M	240 M
Long-Term Debt	592 M	592 M	547 M	547 M	711 M	711 M	713 M	713 M	614 M	614 M	608 M	608 M	319 M	319 M	301 M	301 M	341 M	341 M	278 M	278 M	476 M	476 M	323 M	323 M	338 M	338 M	363 M	377 M	392 M	393 M	307 M	311 M	14.4 M	18.8 M	24.6 M	24.6 M	25.6 M	25.6 M	-	-	26.2 M	36 M	37.1 M	45.8 M	56.4 M	65.5 M	36.5 M
Deferred Revenue Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	263 M	-	278 M	-	265 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6.5 M	-	-
Deferred Tax Liabilities Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	318 K	-	2.68 M	-	2.52 M	-	4.78 M	-	3.51 M	762 K	9.67 M	-	15.7 M	-	21.1 M	22.6 M	29.7 M	-	21.2 M	-	-	-	15.6 M	18.1 M	-	944 K	6.5 M	1.14 M	881 K
Total Non Current Liabilities	1.01 B	1.01 B	1.01 B	1.01 B	1.09 B	1.09 B	1.08 B	1.08 B	969 M	969 M	905 M	905 M	646 M	646 M	541 M	541 M	639 M	639 M	541 M	541 M	757 M	757 M	590 M	590 M	342 M	342 M	367 M	378 M	401 M	409 M	323 M	327 M	35.5 M	49.2 M	54.4 M	54.4 M	46.8 M	46.8 M	18.6 M	18.6 M	41.8 M	54.1 M	40.2 M	46.8 M	171 M	66.7 M	37.4 M
Total Liabilities	1.55 B	1.55 B	1.57 B	1.57 B	1.54 B	1.54 B	1.47 B	1.47 B	1.26 B	1.26 B	1.28 B	1.28 B	1.05 B	1.05 B	1.1 B	1.1 B	1.1 B	1.1 B	1.03 B	1.03 B	1.17 B	1.17 B	1 B	1 B	927 M	927 M	925 M	836 M	897 M	908 M	801 M	733 M	454 M	466 M	473 M	473 M	409 M	409 M	384 M	384 M	378 M	394 M	367 M	330 M	323 M	346 M	277 M
Retained Earnings	312 M	312 M	318 M	318 M	181 M	181 M	146 M	146 M	122 M	122 M	94.1 M	94.1 M	98.4 M	98.4 M	69.4 M	69.4 M	82.1 M	82.1 M	-9.97 M	-9.97 M	34.4 M	32 M	-94.5 M	-94.5 M	1.96 M	1.96 M	-53.3 M	29.8 M	5.01 M	29.4 M	71.8 M	55.6 M	120 M	-	183 M	183 M	251 M	251 M	235 M	235 M	288 M	76 M	248 M	641 M	725 M	586 M	578 M
Accumulated Other Comprehensive Income Loss	-29.4 M	-29.4 M	-30.1 M	-30.1 M	-	19.6 M	-	21.1 M	-	20 M	-	11.7 M	-	375 K	-283 M	375 K	-251 M	375 K	-221 M	375 K	-178 M	375 K	-178 M	375 K	-155 M	485 K	-135 M	-117 M	-109 M	485 K	-101 M	485 K	-90.4 M	-	-82.6 M	485 K	-73.2 M	485 K	485 K	485 K	-56.8 M	-39.6 M	-101 K	-31.2 M	-31.8 M	-24.1 M	-20.7 M
Total Stockholders Equity	433 M	433 M	500 M	500 M	381 M	381 M	341 M	341 M	276 M	276 M	235 M	235 M	223 M	223 M	194 M	194 M	216 M	216 M	98.7 M	111 M	154 M	154 M	27 M	27 M	116 M	116 M	51.2 M	134 M	110 M	134 M	154 M	160 M	202 M	280 M	288 M	288 M	356 M	356 M	339 M	339 M	447 M	808 M	352 M	790 M	833 M	735 M	684 M
Total Liabilities And Stockholders Equity	2.51 B	2.51 B	2.54 B	2.54 B	2.36 B	2.36 B	2.04 B	2.04 B	1.75 B	1.75 B	1.74 B	1.74 B	1.5 B	1.5 B	1.51 B	1.51 B	1.59 B	1.59 B	1.4 B	1.4 B	1.43 B	1.43 B	1.12 B	1.12 B	1.12 B	1.12 B	1.05 B	1.04 B	1.08 B	1.12 B	1.04 B	984 M	754 M	818 M	833 M	833 M	844 M	844 M	806 M	806 M	832 M	1.2 B	729 M	1.12 B	1.17 B	1.08 B	961 M
Total Investments	186 M	186 M	189 M	189 M	213 M	219 M	193 M	219 M	167 M	168 M	121 M	121 M	73.5 M	74 M	54.3 M	54.9 M	31.8 M	47.5 M	18.2 M	107 M	15.2 M	134 M	141 M	131 M	1.64 M	145 M	245 M	245 M	246 M	338 M	247 M	388 M	314 M	314 M	314 M	459 M	344 M	459 M	414 M	414 M	357 M	799 M	428 M	778 M	797 M	728 M	688 M
Total Debt	790 M	790 M	787 M	787 M	812 M	812 M	832 M	832 M	623 M	623 M	617 M	617 M	477 M	477 M	488 M	488 M	521 M	521 M	424 M	424 M	520 M	520 M	374 M	374 M	404 M	404 M	414 M	420 M	432 M	439 M	346 M	390 M	74.3 M	116 M	115 M	115 M	117 M	117 M	98.9 M	98.9 M	134 M	118 M	129 M	136 M	145 M	154 M	107 M
Net Debt	419 M	419 M	242 M	242 M	450 M	450 M	630 M	630 M	564 M	564 M	424 M	424 M	429 M	429 M	381 M	381 M	363 M	363 M	334 M	334 M	461 M	461 M	310 M	310 M	325 M	325 M	307 M	312 M	250 M	106 M	60.7 M	108 M	52 M	87.2 M	63.9 M	63.9 M	58.8 M	58.8 M	28 M	28 M	41.4 M	69.7 M	111 M	130 M	111 M	150 M	85.8 M

All numbers in RUB currency

Balance Sheet is a fundamental financial report of Институт стволовых клеток человека, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis

Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability.
Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-	2.43 %	$ 254 M	Germany
Acorda Therapeutics ACOR	-	-24.86 %	$ 820 K	USA
AbbVie ABBV	$ 208.84	-2.86 %	$ 369 B	USA
AbCellera Biologics ABCL	$ 3.52	0.28 %	$ 1.05 B	Canada
Grifols, S.A. GRFS	$ 8.24	-0.12 %	$ 6.83 B	Spain
Ascendis Pharma A/S ASND	$ 229.25	0.44 %	$ 5 B	Danmark
I-Mab IMAB	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	-	-	$ 40.3 B	USA
Genfit SA GNFT	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	-	-13.47 %	$ 169 M	France
Aeterna Zentaris AEZS	-	5.93 %	$ 314 M	Canada
Aeglea BioTherapeutics AGLE	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	-	-	$ 26.5 M	USA
Akero Therapeutics AKRO	-	-	$ 3.67 B	USA
Midatech Pharma plc MTP	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	-	-1.52 %	$ 24.7 M	USA
ANI Pharmaceuticals ANIP	$ 74.21	-2.3 %	$ 1.43 B	USA
Adverum Biotechnologies ADVM	-	-	$ 86.2 M	USA
Advaxis ADXS	-	-9.65 %	$ 45.9 M	USA
Autolus Therapeutics plc AUTL	$ 1.41	2.17 %	$ 375 M	Britain
AgeX Therapeutics AGE	-	-10.17 %	$ 12.2 K	USA
Cocrystal Pharma COCP	$ 1.51	48.04 %	$ 17 M	USA
Applied Molecular Transport AMTI	-	-	$ 10.1 M	USA
AIkido Pharma AIKI	-	1.93 %	$ 17.4 M	USA
Akouos AKUS	-	0.23 %	$ 488 M	USA
Allena Pharmaceuticals ALNA	-	3.16 %	$ 1.9 M	USA
BioMarin Pharmaceutical BMRN	$ 55.5	-3.04 %	$ 10.6 B	USA
Alpine Immune Sciences ALPN	-	-	$ 2.17 B	USA
Aileron Therapeutics ALRN	-	10.36 %	$ 9.8 M	USA
Arcturus Therapeutics Holdings ARCT	$ 8.03	2.29 %	$ 220 M	Israel
Adaptive Biotechnologies Corporation ADPT	$ 14.81	2.63 %	$ 2.25 B	USA
Altimmune ALT	$ 3.34	7.05 %	$ 294 M	USA
BioNTech SE BNTX	$ 91.18	1.97 %	$ 27.2 B	Germany
Amgen AMGN	$ 347.94	-1.51 %	$ 187 B	USA
Aurinia Pharmaceuticals AUPH	$ 15.61	0.9 %	$ 2.1 B	Canada
Bristol-Myers Squibb Company BMY	$ 59.6	-2.45 %	$ 121 B	USA
Aptose Biosciences APTO	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	-	-39.0 %	$ 4.57 M	USA
CureVac N.V. CVAC	-	-	$ 867 M	Germany
Burford Capital Limited BUR	$ 4.14	-2.59 %	$ 683 M	Britain
BioCryst Pharmaceuticals BCRX	$ 9.02	-3.84 %	$ 1.86 B	USA
Avenue Therapeutics ATXI	-	-52.27 %	$ 4.45 M	USA
Atea Pharmaceuticals AVIR	$ 5.76	1.95 %	$ 469 M	USA
BeiGene, Ltd. BGNE	-	0.49 %	$ 251 B	Cayman-islands
AVROBIO AVRO	-	1083.1 %	$ 745 M	USA
Cellectis S.A. CLLS	$ 3.41	1.19 %	$ 116 M	France
Biogen BIIB	$ 177.34	-3.5 %	$ 26 B	USA
Axcella Health AXLA	-	-16.42 %	$ 249 M	USA
Axon Enterprise AXON	$ 412.81	-2.54 %	$ 31.3 B	USA

Институт стволовых клеток человека Balance Sheet 2006-2026 | ISKJ

Annual Balance Sheet Институт стволовых клеток человека

Cash And Cash Equivalents

Total Current Assets

Property Plant Equipment Net

Intangible Assets

Goodwill And Intangible Assets

Long-Term Investments

Tax Assets

Total Non Current Assets

Total Assets

Account Payables

Short-Term Debt

Tax Payables

Deferred Revenue

Total Current Liabilities

Long-Term Debt

Deferred Revenue Non Current

Deferred Tax Liabilities Non Current

Total Non Current Liabilities

Total Liabilities

Retained Earnings

Accumulated Other Comprehensive Income Loss

Total Stockholders Equity

Total Liabilities And Stockholders Equity

Total Investments

Total Debt

Net Debt